Free Trial
NASDAQ:XNCR

Xencor Q3 2024 Earnings Results & Report

Xencor logo
$37.09 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$37.10 +0.00 (+0.01%)
As of 03:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Xencor beat analyst earnings expectations but missed on revenue in its Q3 2024 results, released November 6, 2024. The company reported EPS of -$0.71 versus the -$0.98 consensus estimate, while revenue of $10.70 million fell short of the $14.59 million estimate by $3.89 million. Revenue decreased 81.9% year over year.

Earnings Announcement Details

Quarter
Q3 2024
Report Date
Time
After Market Closes
Conference Call Date
Conference Call
6:00 PM ET

Xencor EPS Results

Actual EPS
-$0.71
Consensus EPS
-$0.98
Beat/Miss
Beat by +$0.27
One Year Ago EPS
-$0.40
EPS Beat Rate
6 of last 8 quarters

Xencor Revenue Results

Actual Revenue
$10.70 million
Expected Revenue
$14.59 million
Beat/Miss
Missed by -$3.89 million
YoY Revenue Growth
-81.90%

Xencor Q3 2024 Earnings FAQ

Xencor (NASDAQ:XNCR) reported earnings of -$0.71 per share for Q3 2024, beating the consensus estimate of -$0.98. The report was announced on Wednesday, November 6, 2024.

Xencor reported revenue of $10.70 million for Q3 2024, against a consensus estimate of $14.59 million.

Xencor Earnings Headlines

$0. Later: $29.97.
Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that link expires, it returns to its usual price of $29.97. The content stays the same - plain-English lessons and a handful of proven techniques - only the price changes. Waiting means paying for something you could have gotten for free.tc pixel
Xencor (NASDAQ:XNCR) Stock Rating Raised to "Buy" at Wall Street Zen
See More Xencor Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Xencor? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xencor and other key companies, straight to your email.

About Xencor

Xencor (NASDAQ:XNCR) is a clinical-stage biopharmaceutical company that discovers and develops engineered antibody therapeutics for cancer and autoimmune diseases. The company’s XmAb technology platform modifies antibody structures to create treatments with properties such as enhanced immune-cell activity or the ability to bind to more than one target.

Xencor advances its own drug candidates and works with other biopharmaceutical companies through research collaborations and licensing agreements. Its development programs include antibody-based approaches designed to engage immune cells or block disease-related targets. The company is headquartered in Monrovia, California, and its collaborations extend its work with partners beyond the United States.

Founded in 1997, Xencor is led by co-founder and Chief Executive Officer Bassil I. Dahiyat, Ph.D. Its focus is on developing and partnering antibody medicines rather than operating as a broad commercial drug manufacturer.

View Xencor Profile